research Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
Search
for
Sort by
Research
30 / 1000+ results research Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
research Tyrosine Kinase Inhibitors: A Review on Pharmacology, Metabolism, and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
research Janus Kinase Inhibitors in Dermatology: A Systematic Review
JAK inhibitors help with skin conditions but need more research on dosing and safety.
research The Auxin-Regulated CrRLK1L Kinase ERULUS Controls Cell Wall Composition During Root Hair Tip Growth
ERULUS controls root hair growth by regulating cell wall composition and pectin activity.
research The Emerging Role of Janus Kinase Inhibitors in the Treatment of Autoimmune and Inflammatory Diseases
Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study
Baricitinib is effective and safe for treating severe alopecia areata.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Topical Application of a Protein Kinase C Inhibitor Reduces Skin and Hair Pigmentation
Applying a specific inhibitor lightens skin and hair color.
research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Inhibiting Janus Kinases to Treat Alopecia Areata
JAK inhibitors might help treat alopecia areata.
research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Cyclosporin A Promotes Hair Epithelial Cell Proliferation and Modulates Protein Kinase C Expression and Translocation in Hair Epithelial Cells
Cyclosporin A promotes hair cell growth and affects protein kinase C levels.
research Janus Kinase (JAK) Inhibitors for the Treatment of Skin and Hair Disorders: A Review of Literature
JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
research Frontal Fibrosing Alopecia Shows Robust T Helper 1 and Janus Kinase 3 Skewing
Frontal fibrosing alopecia is linked to increased immune system activity and reduced stem cells, suggesting early treatment targeting this pathway might prevent hair follicle damage.
research Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
research Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
research Several Selective Protein Kinase C Inhibitors Including Procyanidins Promote Hair Growth
Certain substances that block a specific protein help promote hair growth.
research Foxn1 Promotes Keratinocyte Differentiation by Regulating the Activity of Protein Kinase C
Foxn1 helps skin cells mature by controlling a specific protein's activity.
research Adverse Cutaneous Reactions to the New Second-Generation Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib) in Chronic Myeloid Leukemia
Many patients on new leukemia drugs had mild to moderate skin reactions.
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
research The Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata: A Systematic Review
Janus kinase inhibitors show promise for treating alopecia areata but need more research for confirmation.
research Skin-Specific Regulation of SREBP Processing and Lipid Biosynthesis by Glycerol Kinase 5
A gene called Gk5 controls lipid production in the skin and affects hair growth.
research The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.
research A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.
research Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
research Janus Kinase Inhibitors For Alopecia Areata
JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
research Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors
New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
research Janus Kinase Inhibitors: An Innovative Treatment for Alopecia Areata
New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.